The Regulation of Platelet Life Span

Platelets

Volumn , Issue , 2013, Pages 51-65

  Josefsson, Emma C ^a   Dowling, Mark R ^b   Lebois, Marion ^a   Kile, Benjamin T ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882725666     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387837-3.00003-1     Document Type: Chapter

References (166)

1. Duke W.W. The relation of blood platelets to hemorrhagic disease. J Am Med Assoc 1910, 250(9):1201-1209.
2. Gaydos L.A., Freireich E.J., Mantel N. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia. N Engl J Med 1962, 266:905-909.
3. Han T., Stutzman L., Cohen E., Kim U. Effect of platelet transfusion on hemorrhage in patients with acute leukemia. An autopsy study. Cancer 1966, 19:1937-1942.
4. Stefanini M., Dameshek W. Collection, preservation and transfusion of platelets; with special reference to the factors affecting the survival rate and the clinical effectiveness of transfused platelets. N Engl J Med 1953, 248:797-802.
5. Cohen J.A., Leeksma C.H. Determination of the life span of human blood platelets using labelled diisopropylfluorophosphonate. J Clin Invest 1956, 35(9):964-969.
6. Hirsch E.O., Gardner F.H. The transfusion of human blood platelets with a note on the transfusion of granulocytes. J Lab Clin Med 1952, 39(4):556-569.
7. Leeksma C., Cohen J. Determination of the life of human blood platelets using labelled diisopropylfluorophosphanate. Nature 1955, 175:552-553.
8. Hoffmeister K.M., Felbinger T.W., Falet H., Denis C.V., Bergmeier W., Mayadas T.N., et al. The clearance mechanism of chilled blood platelets. Cell 2003, 112:87-97.
9. Li J., Xia Y., Bertino A.M., Coburn J.P., Kuter D.J. The mechanism of apoptosis in human platelets during storage. Transfusion 2000, 40:1320-1329.
10. Cazenave J.P., Isola H., Waller C., Mendel I., Kientz D., Laforet M., et al. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011, 51:622-629.
11. Gunson H.H., Makar Y.F., Fletcher S. Five-day storage of platelet concentrates. I. In vitro studies. Clin Lab Haematol 1983, 5:75-82.
12. Holme S., Murphy S. Coulter Counter and light transmission studies of platelets exposed to low temperature, ADP, EDTA, and storage at 22 degrees. J Lab Clin Med 1980, 96:480-493.
13. Holme S., Murphy S. Platelet storage at 22 degrees C for transfusion: interrelationship of platelet density and size, medium pH, and viability after in vivo infusion. J Lab Clin Med 1983, 101:161-174.
14. Holme S., Vaidja K., Murphy S. Platelet storage at 22 degrees C: effect of type of agitation on morphology, viability, and function in vitro. Blood 1978, 52:425-435.
15. Murphy S. Platelet transfusion. Prog Hemost Thromb 1976, 3:289-310.
16. Murphy S., Gardner F.H. The effect of temperature on platelet viability. Vox Sang 1969, 17:22.
17. Murphy S., Gardner F.H. Effect of storage temperature on maintenance of platelet viability: deleterious effect of refrigerated storage. N Engl J Med 1969, 280:1094-1098.
18. Murphy S., Sayar S.N., Gardner F.H. Storage of platelet concentrates at 22 degrees C. Blood 1970, 35:549-557.
19. Ohto H., Nollet K.E. Overview on platelet preservation: better controls over storage lesion. Transfus Apher Sci 2011, 44:321-325.
20. Bertino A.M., Qi X.Q., Li J., Xia Y., Kuter D.J. Apoptotic markers are increased in platelets stored at 37 degrees C. Transfusion 2003, 43:857-866.
21. Hartley P.S., Savill J., Brown S.B. The death of human platelets during incubation in citrated plasma involves shedding of CD42b and aggregation of dead platelets. Thromb Haemost 2006, 95:100-106.
22. Brown M.B., Hayward O.C., Powell E.O., Witts L.J. The destruction of transfused erythrocytes in anemia. J Path Bact 1944, 56:81.
23. Callender S.E., Nickel J.F., Moore C.V., Powell E.O. Sickle cell disease; studied by measuring the survival of transfused red blood cells. J Lab Clin Med 1949, 34:90-104.
24. Callender S.T., Powell E.O., Witts L.J. The life-span of the red cell in man. J Path Bact 1945, 57:129-139.
25. Dacie J.V. Transfusion of saline-washed red cells in nocturnal haemoglobinuria (Marchiafava-Micheli disease). Clin Sci 1948, 7:65-75.
26. Schiodt E. On the duration of life of the red blood corpuscles. Acta Med Scandinav 1938, 95:49.
27. Dornhorst A.C. The interpretation of red cell survival curves. Blood 1951, 6:1284-1292.
28. Mustard J., Rowsell H., Murphy E. Platelet economy (platelet survival and turnover). Br J Haematol 1966, 12:1-24.
29. Murphy E. The estimation of blood platelet survival. 3. The robustness of the basic models. Thromb Diath Haemorrh 1971, 26:431-448.
30. Murphy E., Francis M. The estimation of blood platelet survival. I. General principles of the study of cell survival. Thromb Diath Haemorrh 1969, 22:281-295.
31. Murphy E., Francis M. The estimation of blood platelet survival. II. The multiple hit model. Thromb Diath Haemorrh 1971, 25:53-80.
32. Murphy E.A., Robinson G.A., Rowsell H.C., Mustard J.F. The pattern of platelet disappearance. Blood 1967, 30:26-38.
33. Aranda E., Pizarro M., Pereira J., Mezzano D. Accumulation of 5-hydroxytryptamine by aging platelets: studies in a model of suppressed thrombopoiesis in dogs. Thromb Haemost 1994, 71:488-492.
34. Mezzano D., del Pino G.E., Montesinos M., Garcia M.E., Aranda E., Foradori A. Platelet 5-hydroxytryptamine increases with platelet age in dogs. Thromb Haemost 1991, 66:254-258.
35. Rand M., Greenberg J., Packham M., Mustard J. Density subpopulations of rabbit platelets: size, protein, and sialic acid content, and specific radioactivity changes following labeling with 35S-sulfate in vivo. Blood 1981, 57:741-746.
36. Zucker M.B., Friedman B.K., Rapport M.M. Identification and quantitative determination of serotonin (5-hydroxytryptamine) in blood platelets. Proc Soc Exp Biol Med 1954, 85:282-285.
37. Harker L.A. The kinetics of platelet production and destruction in man. Clinics in Haematology 1977, 6:671-693.
38. ICSH Recommended methods for radioisotope platelet survival studies: by the panel on Diagnostic Application of Radioisotopes in Hematology, International Committee for Standardization in Hematology. Blood 1977, 50:1137-1144.
39. Slichter S.J., Bolgiano D., Corson J., Jones M.K., Christoffel T. Extended storage of platelet-rich plasma-prepared platelet concentrates in plasma or plasmalyte. Transfusion 2010, 50:2199-2209.
40. Beer J.H., Buchi L., Steiner B. Glycocalicin: a new assay-The normal plasma levels and its potential usefulness in selected diseases. Blood 1994, 83:691-702.
41. Kurata Y., Hayashi S., Kiyoi T., Kosugi S., Kashiwagi H., Honda S., et al. Diagnostic value of tests for reticulated platelets, plasma glycocalicin, and thrombopoietin levels for discriminating between hyperdestructive and hypoplastic thrombocytopenia. Am J Clin Pathol 2001, 115:656-664.
42. Steinberg M.H., Kelton J.G., Coller B.S. Plasma glycocalicin. An aid in the classification of thrombocytopenic disorders. N Engl J Med 1987, 317:1037-1042.
43. Ault K., Knowles C. In vivo biotinylation demonstrates that reticulated platelets are the youngest platelets in circulation. Exp Hematol 1995, 23:996-1001.
44. Dale G.L., Friese P., Hynes L.A., Burstein S.A. Demonstration that thiazole-orange-positive platelets in the dog are less than 24 hours old. Blood 1995, 85(7):1822-1825.
45. Matic G.B., Chapman E.S., Zaiss M., Rothe G., Schmitz G. Whole blood analysis of reticulated platelets: improvements of detection and assay stability. Cytometry 1998, 34:229-234.
46. Briggs C., Kunka S., Hart D., Oguni S., Machin S.J. Assessment of an immature platelet fraction (IPF) in peripheral thrombocytopenia. Br J Haematol 2004, 126:93-99.
47. Kienast J., Schmitz G. Flow cytometric analysis of thiazole orange uptake by platelets: a diagnostic aid in the evaluation of thrombocytopenic disorders. Blood 1990, 75:116-121.
48. Barsam S.J., Psaila B., Forestier M., Page L.K., Sloane P.A., Geyer J.T., et al. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood 2011, 117:5723-5732.
49. Kresie L., Benavides D., Bollinger P., Walters J., Pierson D., Richmond T., et al. Performance evaluation of the application of body fluids on the Sysmex XE-2100 series automated hematology analyzer. Lab Hematol 2005, 11:24-30.
50. Pons I., Monteagudo M., Lucchetti G., Munoz L., Perea G., Colomina I., et al. Correlation between immature platelet fraction and reticulated platelets. Usefulness in the etiology diagnosis of thrombocytopenia. Eur J Haematol 2010, 85:158-163.
51. Saxon B.R., Mody M., Blanchette V.S., Freedman J. Reticulated platelet counts in the assessment of thrombocytopenic disorders. Acta Paediatr Suppl 1998, 424:65-70.
52. Michelson A.D., Barnard M.R., Hechtman H.B., MacGregor H., Connolly R.J., Loscalzo J., et al. In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function. Proc Natl Acad Sci USA 1996, 93:11877-11882.
53. Baker G.R., Sullam P.M., Levin J. A simple, fluorescent method to internally label platelets suitable for physiological measurements. Am J Hematol 1997, 56:17-25.
54. Hoffmeister K.M., Josefsson E.C., Isaac N.A., Clausen H., Hartwig J.H., Stossel T.P. Glycosylation restores survival of chilled blood platelets. Science 2003, 301:1531-1534.
55. Bergmeier W., Piffath C.L., Cheng G., Dole V.S., Zhang Y., von Andrian U.H., et al. Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbalpha shedding from platelets in vitro and in vivo. Circ Res 2004, 95:677-683.
56. Pleines I., Eckly A., Elvers M., Hagedorn I., Eliautou S., Bender M., et al. Multiple alterations of platelet functions dominated by increased secretion in mice lacking Cdc42 in platelets. Blood 2010, 115:3364-3373.
57. Dowling M.R., Josefsson E.C., Henley K.J., Hodgkin P.D., Kile B.T. Platelet senescence is regulated by an internal timer, not damage inflicted by hits. Blood 2010, 116:1776-1778.
58. Coupland L.A., Cromer D., Davenport M.P., Parish C.R. A novel fluorescent-based assay reveals that thrombopoietin signaling and Bcl-X(L) influence, respectively, platelet and erythrocyte lifespans. Experimental Hematology 2010, 38:453-461. e1.
59. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
60. Strasser A., Cory S., Adams J.M. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J 2011, 30:3667-3683.
61. Youle R.J., Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008, 9:47-59.
62. Galluzzi L., Vitale I., Abrams J.M., Alnemri E.S., Baehrecke E.H., Blagosklonny M.V., et al. Molecular definitions of cell death subroutines: recommendations of the Nomenclature Committee on Cell death 2012. Cell Death Differ 2012, 19:107-120.
63. Boldin M.P., Goncharov T.M., Goltsev Y.V., Wallach D. Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 1996, 85:803-815.
64. Kischkel F.C., Hellbardt S., Behrmann I., Germer M., Pawlita M., Krammer P.H., et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J 1995, 14:5579-5588.
65. Varfolomeev E.E., Schuchmann M., Luria V., Chiannilkulchai N., Beckmann J.S., Mett I.L., et al. Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity 1998, 9:267-276.
66. Oberst A., Dillon C.P., Weinlich R., Mccormick L.L., Fitzgerald P., Pop C., et al. Catalytic activity of the caspase-8-FLIPL complex inhibits RIPK3-dependent necrosis. Nature 2011, 471:363-367.
67. Kluck R.M., Bossy-Wetzel E., Green D.R., Newmeyer D.D. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997, 275:1132-1136.
68. Li P., Nijhawan D., Budihardjo I., Srinivasula S.M., Ahmad M., Alnemri E.S., et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997, 91:479-489.
69. Villunger A., Labi V., Bouillet P., Adams J., Strasser A. Can the analysis of BH3-only protein knockout mice clarify the issue of "direct versus indirect" activation of Bax and Bak?. Cell Death Differ 2011, 18:1545-1546.
70. Willis S., Chen L., Dewson G., Wei A., Naik E., Fletcher J., et al. Pro-apoptotic Bak is sequestered by Mc1-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev 2005, 19:1294-1305.
71. Willis S.N., Fletcher J.I., Kaufmann T., van Delft M.F., Chen L., Czabotar P.E., et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007, 315:856-859.
72. Kuwana T., Bouchier-Hayes L., Chipuk J.E., Bonzon C., Sullivan B.A., Green D.R., et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005, 17:525-535.
73. Letai A., Bassik M.C., Walensky L.D., Sorcinelli M.D., Weiler S., Korsmeyer S.J. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2002, 2:183-192.
74. Ren D., Tu H.-C., Kim H., Wang G.X., Bean G.R., Takeuchi O., et al. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science 2010, 330:1390-1393.
75. Lindsten T., Ross A., King A., Zong W., Rathmell J., Shiels H., et al. The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Mol Cell 2000, 6:1389-1399.
76. Cheng E., Wei M., Weiler S., Flavell R., Mak T., Lindsten T., et al. BCL-2, BCL-xL sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. Mol Cell 2001, 8:705-711.
77. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., Ross A.J., et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292:727-730.
78. Zong W., Lindsten T., Ross A., MacGregor G., Thompson C. BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev 2001, 15:1481-1486.
79. Egle A., Harris A.W., Bath M.L., O'Reilly L., Cory S. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood 2004, 103:2276-2283.
80. Ogilvy S., Metcalf D., Print C., Bath M., Harris A., Adams J. Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci USA 1999, 96:14943-14948.
81. Motoyama N., Wang F., Roth K., Sawa H., Nakayama K., Nakayama K., et al. Massive cell death of immature hematopoietic cells and neurons in Bcl-x deficient mice. Science 1995, 267:1506-1510.
82. Sentman C.L., Shutter J.R., Hockenbery D, Kanagawa O., Korsmeyer S.J. bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991, 67:879-888.
83. Opferman J., Iwasaki H., Ong C., Suh H., Mizuno S., Akashi K., et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005, 307:1101-1104.
84. Opferman J., Letai A., Beard C., Sorcinelli M., Ong C., Korsmeyer S. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003, 426:671-676.
85. Steimer D.A., Boyd K., Takeuchi O., Fisher J.K., Zambetti G.P., Opferman J.T. Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function. Blood 2009, 113:2805-2815.
86. Weber A., Boger R., Vick B., Urbanik T., Haybaeck J., Zoller S., et al. Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology 2010, 51:1226-1236.
87. Mason K.D., Carpinelli M.R., Fletcher J.I., Collinge J.E., Hilton A.A., Ellis S., et al. Programmed anuclear cell death delimits platelet life span. Cell 2007, 128:1173-1186.
88. Josefsson E.C., James C., Henley K.J., Debrincat M.A., Rogers K.L., Dowling M.R., et al. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med 2011, 208:2017-2031.
89. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
90. Tse C., Shoemaker A.R., Adickes J., Anderson M.G., Chen J., Jin S., et al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008, 68:3421-3428.
91. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
92. Zhang H., Nimmer P.M., Tahir S.K., Chen J., Fryer R.M., Hahn K.R., et al. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 2007, 14:943-951.
93. Dasgupta S.K., Argaiz E.R., Mercado J.E., Maul H.O., Garza J., Enriquez A.B., et al. Platelet senescence and phosphatidylserine exposure. Transfusion 2010, 50:2167-2175.
94. Schoenwaelder S.M., Yuan Y., Josefsson E.C., White M.J., Yao Y., Mason K.D., et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood 2009, 114:663-666.
95. van Delft M., Wei A., Mason K., Vandenberg C., Chen L., Czabotar P., et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006, 10:389-399.
96. Schoenwaelder S.M., Jarman K.E., Gardiner E.E., Hua M., Qiao J., White M.J., et al. Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood 2011, 118:1663-1674.
97. Vogler M., Hamali H.A., Sun X.M., Bampton E.T., Dinsdale D., Snowden R.T., et al. BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood 2011, 117:7145-7154.
98. Gandhi L., Camidge D.R., Ribeiro de Oliveira M., Bonomi P., Gandara D., Khaira D., et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011, 29:909-916.
99. Wilson W.H., O'Connor O.A., Czuczman M.S., LaCasce A.S., Gerecitano J.F., Leonard J.P., et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 2010, 11:1149-1159.
100. Kodama T., Takehara T., Hikita H., Shimizu S., Shigekawa M., Li W., et al. BH3-only activator proteins Bid and Bim are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by Bcl-xL deficiency: molecular requisites for the mitochondrial pathway to apoptosis in platelets. J Biol Chem 2011, 286:13905-13913.
101. Batar P., Dale G. Platelet turnover and aging. Platelets 2002, Academic Press/Elsevier, San Diego, :53-64. A.D. Michelson (Ed.).
102. Hanson S.R., Slichter S.J. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. Blood 1985, 66:1105-1109.
103. Chen S., Dai Y., Harada H., Dent P., Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 2007, 67:782-791.
104. Domina A.M., Vrana J.A., Gregory M.A., Hann S.R., Craig R.W. MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 2004, 23:5301-5315.
105. Maurer U., Charvet C., Wagman A.S., Dejardin E., Green D.R. Glycogen synthase kinase-3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Mol Cell 2006, 21:749-760.
106. Kelly P.N., White M.J., Goschnick M.W., Fairfax K.A., Tarlinton D.M., Kinkel S.A., et al. Individual and overlapping roles of BH3-only proteins Bim and Bad in apoptosis of lymphocytes and platelets and in suppression of thymic lymphoma development. Cell Death Differ 2010, 17:1655-1664.
107. Catani M.V., Gasperi V., Evangelista D., Finazzi Agro A., Avigliano L., Maccarrone M. Anandamide extends platelets survival through CB(1)-dependent Akt signaling. Cell Mol Life Sci 2010, 67:601-610.
108. Youle R.J. Cell biology. Cellular demolition and the rules of engagement. Science 2007, 315:776-777.
109. Kodama T., Takehara T., Hikita H., Shimizu S., Li W., Miyagi T., et al. Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in mice. Gastroenterology 2010, 138:2487-2498. 98.e1-7.
110. Plenchette S., Moutet M., Benguella M., Gondara J., Guigner F., Coffe C., et al. Early increase in DcR2 expression and late activation of caspases in the platelet storage lesion. Leukemia 2001, 15:1572-1581.
111. Bevers E., Comfurius P., Zwaal R. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta 1983, 736:57-66.
112. Zwaal R.F., Comfurius P., van Deenen L.L. Membrane asymmetry and blood coagulation. Nature 1977, 268:358-360.
113. Dale G.L. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost 2005, 3:2185-2192.
114. Dale G.L., Friese P., Batar P., Hamilton S.F., Reed G.L., Jackson K.W., et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature 2002, 415:175-179.
115. Dale G.L., Remenyi G., Friese P. Quantitation of microparticles released from coated-platelets. J Thromb Haemost 2005, 3:2081-2088.
116. Jackson S.P., Schoenwaelder S.M. Procoagulant platelets: are they necrotic?. Blood 2010, 116:2011-2018.
117. Kulkarni S., Jackson S.P. Platelet factor XIII and calpain negatively regulate integrin alphaIIbbeta3 adhesive function and thrombus growth. J Biol Chem 2004, 279:30697-30706.
118. Nesbitt W.S., Giuliano S., Kulkarni S., Dopheide S.M., Harper I.S., Jackson S.P. Intercellular calcium communication regulates platelet aggregation and thrombus growth. J Cell Biol 2003, 160:1151-1161.
119. Castoldi E., Collins P.W., Williamson P.L., Bevers E.M. Compound heterozygosity for 2 novel TMEM16F mutations in a patient with Scott syndrome. Blood 2011, 117:4399-4400.
120. Suzuki J., Umeda M., Sims P.J., Nagata S. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 2010, 468:834-838.
121. Weiss H.J., Vicic W.J., Lages B.A., Rogers J. Isolated deficiency of platelet procoagulant activity. Am J Med 1979, 67:206-213.
122. Kuypers F.A., Larkin S.K., Emeis J.J., Allison A.C. Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity. Thromb Haemost 2007, 97:478-486.
123. Galan A.M., van Heerde W.L., Escolar G., Ordinas A., Sixma J., de Groot P.G. Antithrombotic action of annexin V proved as efficient as direct inhibition of tissue factor or thrombin. Eur J Clin Invest 2006, 36:633-639.
124. Chen H.H., Vicente C.P., He L., Tollefsen D.M., Wun T.C. Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants. Blood 2005, 105:3902-3909.
125. Kuijpers M.J., Munnix I.C., Cosemans J.M., Vlijmen B.V., Reutelingsperger C.P., Egbrink M.O., et al. Key role of platelet procoagulant activity in tissue factor-and collagen-dependent thrombus formation in arterioles and venules in vivo differential sensitivity to thrombin inhibition. Microcirculation 2008, 15:269-282.
126. Heemskerk J.W., Feijge M.A., Henneman L., Rosing J., Hemker H.C. The Ca2+-mobilizing potency of alpha-thrombin and thrombin-receptor-activating peptide on human platelets: concentration and time effects of thrombin-induced Ca2+ signaling. Eur J Biochem 1997, 249:547-555.
127. Gilio K., van Kruchten R., Braun A., Berna-Erro A., Feijge M.A., Stegner D., et al. Roles of platelet STIM1 and Orai1 in glycoprotein VI- and thrombin-dependent procoagulant activity and thrombus formation. J Biol Chem 2010, 285:23629-23638.
128. Liou J., Kim M.L., Heo W.D., Jones J.T., Myers J.W., Ferrell J.E., et al. STIM is a Ca2+ sensor essential for Ca2+-store-depletion-triggered Ca2+ influx. Curr Biol 2005, 15:1235-1241.
129. Roos J., DiGregorio P.J., Yeromin A.V., Ohlsen K., Lioudyno M., Zhang S., et al. STIM1, an essential and conserved component of store-operated Ca2+ channel function. J Cell Biol 2005, 169:435-445.
130. Varga-Szabo D., Braun A., Kleinschnitz C., Bender M., Pleines I., Pham M., et al. The calcium sensor STIM1 is an essential mediator of arterial thrombosis and ischemic brain infarction. J Exp Med 2008, 205:1583-1591.
131. Varga-Szabo D., Braun A., Nieswandt B. STIM and Orai in platelet function. Cell Calcium 2011, 50:270-278.
132. Vig M., Peinelt C., Beck A., Koomoa D.L., Rabah D., Koblan-Huberson M., et al. CRACM1 is a plasma membrane protein essential for store-operated Ca2+ entry. Science 2006, 312:1220-1223.
133. Yeromin A.V., Zhang S.L., Jiang W., Yu Y., Safrina O., Cahalan M.D. Molecular identification of the CRAC channel by altered ion selectivity in a mutant of Orai. Nature 2006, 443:226-229.
134. Ahmad F., Boulaftali Y., Greene T.K., Ouellette T.D., Poncz M., Feske S., et al. Relative contribution of STIM1 and CalDAG-GEFI to calcium-dependent platelet activation and thrombosis. J Thromb Haemost 2011, 6:2077-2086.
135. Crittenden J.R., Bergmeier W., Zhang Y., Piffath C.L., Liang Y., Wagner D.D., et al. CalDAG-GEFI integrates signaling for platelet aggregation and thrombus formation. Nat Med 2004, 10:982-986.
136. Stefanini L., Roden R.C., Bergmeier W. CalDAG-GEFI is at the nexus of calcium-dependent platelet activation. Blood 2009, 114:2506-2514.
137. Jobe S., Wilson K., Leo L., Raimondi A., Molkentin J., Lentz S., et al. Critical role for the mitochondrial permeability transition pore and cyclophilin D in platelet activation and thrombosis. Blood 2008, 111(3):1257-1265.
138. Fadok V., Voelker D., Campbell P., Cohen J., Bratton D., Henson P. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 1992, 148:2207-2216. (Baltimore, Md: 1950).
139. Verhoven B., Schlegel R.A., Williamson P. Mechanisms of phosphatidylserine exposure, a phagocyte recognition signal, on apoptotic T lymphocytes. J Exp Med 1995, 182:1597-1601.
140. Caserta T., Smith A., Gultice A., Reedy M., Brown T. Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 2003, 8:345-352.
141. Wolf B., Goldstein J., Stennicke H., Beere H., Amarante-Mendes G., Salvesen G., et al. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. Blood Sep 01 1999, 94(5):1683-1692.
142. Cohen Z., Wilson J., Ritter L., McDonagh P. Caspase inhibition decreases both platelet phosphatidylserine exposure and aggregation: caspase inhibition of platelets. Thromb Res 2004, 113:387-393.
143. Leytin V., Allen D., Mykhaylov S., Mis L., Lyubimov E., Garvey B., et al. Pathologic high shear stress induces apoptosis events in human platelets. Biochem Biophys Res Commun 2004, 320:303-310.
144. Leytin V., Mykhaylov S., Starkey A.F., Allen D.J., Lau H., Ni H., et al. Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia. Br J Haematol 2006, 133:78-82.
145. Shcherbina A., Remold-O'Donnell E. Role of caspase in a subset of human platelet activation responses. Blood 1999, 93:4222-4231.
146. Vanags D.M., Orrenius S., Aguilar-Santelises M. Alterations in Bcl-2/Bax protein levels in platelets form part of an ionomycin-induced process that resembles apoptosis. Br J Haematol 1997, 99:824-831.
147. Cecconi F., Alvarez-Bolado G., Meyer B.I., Roth K.A., Gruss P. Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development. Cell 1998, 94:727-737.
148. Hakem R., Hakem A., Duncan G., Henderson J., Woo M., Soengas M., et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell 1998, 94:339-352.
149. Hao Z., Duncan G.S., Chang C.-C., Elia A., Fang M., Wakeham A., et al. Specific ablation of the apoptotic functions of cytochrome C reveals a differential requirement for cytochrome C and Apaf-1 in apoptosis. Cell 2005, 121:579-591.
150. Kuida K., Haydar T., Kuan C., Gu Y., Taya C., Karasuyama H., et al. Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998, 94:325-337.
151. Yoshida H., Kong Y.Y., Yoshida R., Elia A.J., Hakem A., Hakem R., et al. Apaf1 is required for mitochondrial pathways of apoptosis and brain development. Cell 1998, 94:739-750.
152. van Delft M.F., Smith D.P., Lahoud M.H., Huang D.C., Adams J.M. Apoptosis and non-inflammatory phagocytosis can be induced by mitochondrial damage without caspases. Cell Death Differ 2010, 17:821-832.
153. Pereira J., Palomo I., Ocqueteau M., Soto M., Aranda E., Mezzano D. Platelet aging in vivo is associated with loss of membrane phospholipid asymmetry. Thromb Haemost 1999, 82:1318-1321.
154. Pereira J., Soto M., Palomo I., Ocqueteau M., Coetzee L.M., Astudillo S., et al. Platelet aging in vivo is associated with activation of apoptotic pathways: studies in a model of suppressed thrombopoiesis in dogs. Thromb Haemost 2002, 87:905-909.
155. Bergmeier W., Burger P., Piffath C., Hoffmeister K., Hartwig J., Nieswandt B., et al. Metalloproteinase inhibitors improve the recovery and hemostatic function of in vitro-aged or -injured mouse platelets. Blood 2003, 102:4229-4235.
156. Hoffmeister K.M. The role of lectins and glycans in platelet clearance. J Thromb Haemost 2011, 9(suppl 1):35-43.
157. Kotze H., van Wyk V., Badenhorst P., Heyns A., Roodt J., Lotter M. Influence of platelet membrane sialic acid and platelet-associated IgG on ageing and sequestration of blood platelets in baboons. Thromb Haemost 1993, 70:676-680.
158. Soslau G., Giles J. The loss of sialic acid and its prevention in stored human platelets. Thromb Res 1982, 26:443-455.
159. Rand M.L., Packham M.A., Mustard J.F. Survival of density subpopulations of rabbit platelets: use of 51Cr-or 111In-labeled platelets to measure survival of least dense and most dense platelets concurrently. Blood 1983, 61:362-367.
160. Gasic G.J., Gasic T.B., Stewart C.C. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968, 61:46-52.
161. Greenberg J., Packham M.A., Cazenave J.P., Reimers H.J., Mustard J.F. Effects on platelet function of removal of platelet sialic acid by neuraminidase. Lab Invest 1975, 32:476-484.
162. Stenberg P.E., Levin J., Baker G., Mok Y., Corash L. Neuraminidase-induced thrombocytopenia in mice: effects on thrombopoiesis. J Cell Physiol 1991, 147:7-16.
163. Grewal P.K., Uchiyama S., Ditto D., Varki N., Le D.T., Nizet V., et al. The Ashwell receptor mitigates the lethal coagulopathy of sepsis. Nat Med 2008, 14:648-655.
164. Rumjantseva V., Grewal P.K., Wandall H.H., Josefsson E.C., Sorensen A.L., Larson G., et al. Dual roles for hepatic lectin receptors in the clearance of chilled platelets. Nat Med 2009, 15:1273-1280.
165. Sorensen A.L., Rumjantseva V., Nayeb-Hashemi S., Clausen H., Hartwig J.H., Wandall H.H., et al. Role of sialic acid for platelet life span: exposure of beta-galactose results in the rapid clearance of platelets from the circulation by asialoglycoprotein receptor-expressing liver macrophages and hepatocytes. Blood 2009, 114:1645-1654.
166. Grozovsky R., Hoffmeister K.M., Falet H. Novel clearance mechanisms of platelets. Curr Opin Hematol 2010, 17:585-589.